MannKind has closed its acquisition of scPharmaceuticals, bringing Furoscix, a subcutaneous furosemide injection for fluid overload in chronic heart failure and chronic kidney disease, into its portfolio. The deal was executed via a tender offer at $5.35 per share in cash plus a non-tradable contingent value right of up to $1.00 per share tied to regulatory and sales milestones, followed by a short-form merger under Delaware law. scPharmaceuticals is now a wholly owned subsidiary, and its shares have been delisted. The transaction adds a third promoted brand to MannKind’s commercial lineup alongside Afrezza and V-Go, with Tyvaso DPI–related revenues continuing to contribute. Based on Q2 2025, MannKind cites an annualized revenue run rate above $370 million, and it has already filed an sNDA for the Furoscix ReadyFlow autoinjector.
The strategic question is whether MannKind can turn a differentiated, clinically intuitive product into a scaled, payer-accepted site-of-care shift. Furoscix aims squarely at a high-cost pain point: decongestion that typically drives emergency department visits and admissions. If MannKind can standardize outpatient and at-home diuresis pathways with cardiology and nephrology practices, the asset becomes not only a revenue driver but a wedge into the broader cardiometabolic care continuum the company is building.
This matters now because payers are pressing for hospital avoidance, Medicare Advantage is tightening utilization, and heart failure readmissions remain a headline cost center. For patients, convenient subcutaneous diuresis may reduce time to relief and exposure to inpatient risks. For providers, adoption hinges on practicalities: discharge protocols, clinic workflow, training, device reliability, and a clean reimbursement path. The ReadyFlow autoinjector could lower the friction of initiation and monitoring, but Medical Affairs will need to generate real-world evidence on total cost of care, readmission reduction, and patient-reported outcomes to translate enthusiasm into coverage policies and care pathways. Commercial teams will have to solve channel economics—specialty pharmacy versus buy-and-bill—and align with home health, remote monitoring programs, and health system site-of-care initiatives to pull through prescriptions.
For competitors, the move signals that drug-device, decentrally delivered acute interventions are moving from pilots to scaled businesses. While Furoscix has limited direct branded competition, its real rival is entrenched hospital-based IV diuresis and the inertia of status quo workflows. That puts a premium on contracting with IDNs, navigating value-based arrangements with payers, and embedding Furoscix into guideline-informed pathways with cardiologists, nephrologists, and advanced HF clinics. The integration of scPharmaceuticals’ cardiovascular expertise with MannKind’s commercial infrastructure and device know-how is logical; success will depend on whether the combined field model can reach beyond endocrinology into the cardiology ecosystem with credible clinical and economic narratives.
At the portfolio level, the acquisition diversifies MannKind’s revenue away from a heavy royalty dependence and deepens its cardiometabolic positioning, while late-stage inhaled assets in orphan lung disease provide optionality. More broadly, the deal typifies the current M&A cycle: mid-cap acquirers targeting de-risked, revenue-bearing assets and using CVRs to bridge valuation gaps, especially where device-enabled delivery can shorten adoption curves.
The next inflection points are clear. Will the Furoscix autoinjector win timely approval and materially reduce onboarding friction? Can MannKind produce payer-grade RWE that demonstrates avoided admissions at scale and secures consistent coverage across Medicare Advantage plans and large commercial payers? The answers will determine whether this acquisition becomes a cornerstone for a durable cardiometabolic platform—or a test of how quickly an inhaled-drug specialist can master the economics and operations of decentralized acute care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
